


## Precision Medicine


Pipelines	Development & Stage	Target & Indication
<b>MG-D-1609</b> agnostic tumor	NCE, oral Phase II in AU	<ul style="list-style-type: none"> <li>C-Raf allosteric mechanism of action</li> <li>Combined with pDAK biomarker for lung, liver, colorectal, renal cancer etc.</li> </ul>
<b>MG-S-2525</b> pulmonary/respiratory	NCE, oral Phase II in TW	<ul style="list-style-type: none"> <li>Target to MAP3K19</li> <li>Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease, Bronchiectasis, etc.</li> </ul>
<b>MG-D-2020</b> anti-metastasis	NCE, oral Hit-to-Lead	<ul style="list-style-type: none"> <li>Target to meta-1</li> <li>Inhibit the metastasis of cancer cells with Meta1 biomarkers in solid tumors</li> </ul>

- Seek funding opportunities and collaborations to progress our first in class program through IND to clinical phase.
- Identify strategic partners in Asia or Global for our innovative pipeline programs.

## MG-D-1509/MG-D-1609 MoA



## MG-S-2525 MoA



3F., No.11, Ln. 77, Xing'ai Rd., Neihu Dist. Taipei City 114, Taiwan



**Maggie Lu Ph.D.** General Manager  
E-mail : [maggie@metagone.com.tw](mailto:maggie@metagone.com.tw)

**Simon Huang** Executive Vice President  
E-mail : [simon@metagone.com.tw](mailto:simon@metagone.com.tw)



Website : [www.metagone.com.tw](http://www.metagone.com.tw)



TEL : +886 (2) 2790-6566

